TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30950970
Drug: Intravitreal dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal dexamethasone (DEX) implant (0.7 mg)
Study: 30950970
Drug: Aflibercept (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept (2 mg, 3 monthly injections as loading phase)
Study: 30005098
Drug: Natural ingredient‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural ingredient‐based moisturizing cream
Study: 30005098
Drug: Colloidal oatmeal
Normalized name: Colloidal Oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal oatmeal moisturizing cream
Study: 26254019
Drug: Candesartan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan plus standard medical treatment
Study: 22617632
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) administered in groups of six patients during 12 weekly sessions (n=25)
Study: 20151341
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine 40 mg followed by propofol 2 mg.kg(‐1) (Group 2PL; n = 30)
Study: 20151341
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg.kg(‐1) (Group 3P; n = 30)
Study: 20151341
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg.kg(‐1) (Group 2P; n = 30)
Study: 20151341
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg.kg(‐1) (Group 3P)
Study: 20151341
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg.kg(‐1) (Group 2P)
Study: 20151341
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine 40 mg followed by propofol 2 mg.kg(‐1) (Group 2PL)
Study: 19140507
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with enalapril and prolonged-release verapamil
Study: 19140507
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with enalapril and moxonidine
Study: 11113797
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of ibuprofen taken orally 1 hour before separator placement
Study: 11113797
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of ibuprofen taken orally immediately after separator placement
Study: 8336583
Drug: Continuous daily
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous daily regimen of 0.3 mg CEE and one of three low-dose progestogens (medroxyprogesterone acetate 2.5 mg, levonorgestrel 30 micrograms or norethisterone 350 micrograms)
Study: 8336583
Drug: Continuous daily
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous daily regimen of 0.3 mg CEE and one of three low-dose progestogens
Study: 8336583
Drug: Norethisterone therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone therapy
Study: 25033717
Drug: Vaginal intercourse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal intercourse at least twice a week
Study: 18506512
Drug: Bilateral PEMF
Normalized name: Pemfexy
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bilateral PEMF treatment (n = 14)
Study: 18506512
Drug: Postoperative analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative analgesic medication use
Study: 16170233
Drug: Caffeine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (100 mg in experiments 1 and 3; 150 mg in experiment 2)
Study: 12544035
Drug: Zinc 50
Normalized name: Zinc 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc 50 mg daily
Study: 12544035
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill containing starch
Study: 10857888
Drug: Arm A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: three 8-mg doses of ondansetron IV at 4-hour intervals plus dexamethasone 20 mg IV from the start of chemotherapy followed by dexamethasone 5 mg IV every 12 hours.
Study: 10857888
Drug: Arm B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: three 8-mg doses of ondansetron IV at 24-hour intervals plus dexamethasone 20 mg IV from the start of chemotherapy followed by dexamethasone 5 mg IV every 12 hours.
Study: 10857888
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A and Arm B (comparison of dosing intervals).
Study: 1512162
Drug: Cranial irradiation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial irradiation, 24 Gy and i.t. MTX 10 mg/m2, 6 doses (RT group)
Study: 1512162
Drug: i.t. Ara‐C
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.t. Ara‐C 30 mg/m2 and i.t. MTX 10 mg/m2, 10 doses (ChT group)
Study: 30549358
Drug: Concurrent cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concurrent cetuximab plus docetaxel
Study: 26493812
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 1 g/day
Study: 19845414
Drug: Pharmacotherapy for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy for symptomatic management (anxiety or insomnia)
Study: 17203013
Drug: Haloperidol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (3 mg, oral) in pathological gamblers
Study: 17203013
Drug: Haloperidol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (3 mg, oral) in non-gambler controls
Study: 3602942
Drug: Acetyl salicylic
Normalized name: Acetyl salicylic acid specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl salicylic acid (3 g daily for one week)
Study: 3602942
Drug: Indomethacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (150 mg daily for one week)
Study: 29233548
Drug: Actual weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actual weight-based (AWB) chemotherapy dosing
Study: 22554311
Drug: Fomepizole IV
Normalized name: Fomepizole
DrugBank: Fomepizole (DB01213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fomepizole IV or orally (7 mg/kg)
Study: 22554311
Drug: Oral loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral loading doses of 10‐15 mg/kg, followed by supplemental doses of 3‐10 mg/kg/12 h through 96 hours
Study: 20861293
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg at night
Study: 12851773
Drug: Tolterodine extended-release
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine extended-release 4 mg once daily
Study: 25297064
Drug: EF (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: EF (3.0 g/L oligofructose)
Study: 21288228
Drug: Intravenous remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous remifentanil bolus (0.4 μg/kg) administered immediately after a contraction trigger
Study: 21288228
Drug: Intravenous remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous remifentanil bolus (0.4 μg/kg) administered 140 seconds before the next contraction
Study: 19262478
Drug: Aliskiren alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren alone or in combination with a diuretic or a calcium channel blocker (CCB)
Study: 11709518
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg four times daily)
Study: 3668983
Drug: Colchicine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1.5 mg daily
Study: 21664867
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bevacizumab (10 mg/kg every 2 weeks) and temsirolimus (25 mg weekly; group A)
Study: 21664867
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg/day for 4 weeks followed by 2 weeks off; group B)
Study: 21664867
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of interferon alfa (9 mIU three times per week) and bevacizumab (10 mg/kg every 2 weeks; group C)
Study: 21664867
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bevacizumab and temsirolimus (group A)
Study: 21664867
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of interferon alfa and bevacizumab (group C)
Study: 17537152
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg day(-1))
Study: 14982784
Drug: Indinavir 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 1000 mg every 12 h with nelfinavir (n = 10)
Study: 14982784
Drug: Indinavir 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 1200 mg every 12 h with nelfinavir (n = 7)
Study: 14982784
Drug: Nelfinavir (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir (in combination with indinavir 1000 mg every 12 h) (n = 9)
Study: 11133744
Drug: Liposomal ATRA
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal ATRA (90 mg/m(2) every other day until complete remission or a maximum of 56 days)
Study: 9468068
Drug: Streptokinase or
Normalized name: dornase alfa / streptokinase Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase or combination therapy
Study: 773601
Drug: Methacycline 600
Normalized name: Methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methacycline 600 mg daily for 14 days
Study: 773601
Drug: Ampicillin 2
Normalized name: ampicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 2 gm daily for 14 days
Study: 31764258
Drug: Tablets, ring,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, ring, and injections (TRIO study)
Study: 31764258
Drug: Vaginal products
Normalized name: Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal products (ring, insert, film, and gel) (Quatro study)
Study: 27319277
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and intravenous ibuprofen
Study: 22052276
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using 20% 5‐aminolevulinic acid solution (ALA) and blue light
Study: 22052276
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using ALA with blue light
Study: 17215967
Drug: Glucometer-guided insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucometer-guided insulin injection
Study: 10849057
Drug: RACM regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: RACM regimen (rabeprazole 10 mg bid, amoxicillin 750 mg bid, clarithromycin 200 mg bid, metronidazole 250 mg bid)
Study: 10849057
Drug: RAC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAC regimen (rabeprazole 10 mg bid, amoxicillin 750 mg bid, clarithromycin 200 mg bid)
Study: 9107431
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg of oltipraz daily
Study: 9107431
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of oltipraz weekly
Study: 8260183
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment only
Study: 8260183
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of surgery, radiotherapy and hormone therapy
Study: 8260183
Drug: Aggressive local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive local treatment with hormone therapy
Study: 29397594
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine treatment with polyene phosphatidylcholine capsules)
Study: 27509606
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of lipoic acid (0.6 g) and alprostadil (10 mg)
Study: 10321449
Drug: Moxonidine (antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (antihypertensive doses)
Study: 10321449
Drug: Moxonidine (non-antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (non-antihypertensive doses)
Study: 10321449
Drug: Sympathicolytic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sympathicolytic agents
Study: 7933259
Drug: Noninvasive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive therapy (exercise and medication)
Study: 3202402
Drug: Methylprednisolone, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone, 30 mg/kg per dose, 4 doses every 6 hours
Study: 10690822
Drug: Topical 0.01%
Normalized name: tretinoin topical 0.01% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.01% mitomycin-C eye drops (n = 17)
Study: 8243490
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil 200 mg every 12 h for 7 days
Study: 8243490
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg every 8 h for 7 days
Study: 31108180
Drug: FeNO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FeNO treatment algorithm
Study: 26586093
Drug: Metronomic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy with capecitabine and thalidomide after RFA
Study: 27036656
Drug: Tat Oyi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tat Oyi vaccine (33 µg)
Study: 27036656
Drug: Tat Oyi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tat Oyi vaccine (11 µg)
Study: 27036656
Drug: Tat Oyi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tat Oyi vaccine (99 µg)
Study: 27036656
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 µg Tat Oyi)
Study: 22458392
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (440 mg/day)
Study: 19521723
Drug: Initial chemotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial chemotherapy for breast cancer
Study: 16011670
Drug: H1 receptor
Normalized name: Histamine H1 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 receptor antagonists (H1RA)
Study: 16011670
Drug: H2 receptor
Normalized name: Histamine H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 receptor antagonists (H2RA)
Study: 10367259
Drug: 740 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 740 mg/m2 amifostine administered before chemotherapy
Study: 10367259
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received 2.6 g/m2 5-fluorouracil and 500 mg/m2 folinic acid per week for 6 weeks
Study: 7586593
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of methimazole per day
Study: 7586593
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of methimazole per day
Study: 1934382
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg over 30 minutes followed by 1 mg.kg‐1.hr‐1 for 12 hours)
Study: 1934382
Drug: Desmopressin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (0.3 micrograms/kg over 20 minutes after protamine infusion)
Study: 1934382
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tranexamic acid and desmopressin
Study: 30592459
Drug: Whole cell
Normalized name: pertussis, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole cell pneumococcal vaccine (WCV)
Study: 24534139
Drug: Enhanced Internet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Internet treatment
Study: 22367657
Drug: Levetiracetam (500-2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (500-2000 g/d)
Study: 17685090
Drug: Astaxanthin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin supplementation (2 capsules of 4 mg daily)
Study: 17685090
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 identical-looking capsules)
Study: 10626717
Drug: Isobaric 9.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric 9.75 mg bupivacaine
Study: 10626717
Drug: Hyperbaric 9.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric 9.75 mg bupivacaine
Study: 10626717
Drug: Epidural injections
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injections of 3 ml lidocaine 2%
Study: 21527171
Drug: Nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplementation (energy and protein enriched diet, oral nutritional support, calcium‐vitamin D supplement, telephone counseling by a dietitian) for 3 months postdischarge
Study: 11885181
Drug: Non-coated implants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-coated implants
Study: 11885181
Drug: All implants
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All implants in bone qualities 1 and 2 (BQ-1 and BQ-2)
Study: 11885181
Drug: All implants
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All implants in bone qualities 3 and 4 (BQ-3 and BQ-4)
Study: 1396838
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant therapy with warfarin (n = 102)
Study: 1396838
Drug: Dipyridamole and
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole and aspirin (n = 130)
Study: 29275333
Drug: Adalimumab (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (24 mg/m2 for patients <13 years, 40 mg for others) administered subcutaneously every other week.
Study: 23993735
Drug: Sufentanil 0.2
Normalized name: ropivacaine-sufentanil 0.2%-1 mcg/mL-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.2 ng/ml
Study: 23993735
Drug: Sufentanil 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.4 ng/ml
Study: 23993735
Drug: Sufentanil 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.5 ng/ml
Study: 20883738
Drug: DTaP 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP 0.2 ml
Study: 20883738
Drug: DTaP 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP 0.5 ml
Study: 20883738
Drug: DTaP 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP 0.2 ml and DTaP 0.5 ml
Study: 17653013
Drug: Amiodarone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone treatment (900 mg/day intravenously for the first 2 days, then 600 mg/day)
Study: 14698516
Drug: Neem (Azadirachta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neem (Azadirachta indica) leaf extract dental gel (25 mg/g)
Study: 11696124
Drug: Dexamethasone plus
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone plus low-dose ondansetron (50 microg.kg(‐1) ondansetron i.v.)
Study: 9263718
Drug: Non-invasive diagnosis
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive diagnosis and conservative treatment
Study: 8427724
Drug: Ondansetron (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (16 mg) orally three times daily starting 24 hours after cisplatin
Study: 8427724
Drug: Placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally three times daily starting 24 hours after cisplatin
Study: 8427724
Drug: Ondansetron (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (16 mg)
Study: 27743903
Drug: rexlemestrocel-L 150×10^6
Approvals — FDA: no, EMA: no, PMDA: no
Description: rexlemestrocel-L 150×10^6
Study: 27743903
Drug: rexlemestrocel-L 300×10^6
Approvals — FDA: no, EMA: no, PMDA: no
Description: rexlemestrocel-L 300×10^6
Study: 21996146
Drug: Prasugrel therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel therapy (loading dose 60 mg; maintenance dose 5 mg/day for patients ≥75 years old or ≤60 kg; 10 mg/day for others)
Study: 16294652
Drug: Active management
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active management with medication or referral to a mental health specialist
Study: 12450703
Drug: MMR/V vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR/V vaccine
Study: 8734231
Drug: 0.375% bupivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375% bupivacaine, 0.6 mL.kg‐1 intraperitoneally
Study: 1721980
Drug: Carvedilol (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25-50 mg once daily)
Study: 1721980
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) (25-50 mg once daily)
Study: 31126570
Drug: Vaccinium arctostaphylos
Normalized name: Arctostaphylos tomentosa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinium arctostaphylos berry extract (400 mg capsule, three times daily for 3 months)
Study: 27755056
Drug: Laryngoscope-assisted lightwand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laryngoscope-assisted lightwand technique (group L, n = 82)
Study: 22479361
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin A (200,000 IU) in addition to daily low-dose vitamin A (5000 IU) for 15 days.